NY-PYRAMID-ANALYTICS
16.9.2022 09:01:43 CEST | Business Wire | Press release
The Chief Technology Officer and Co-founder of Pyramid Analytics (Pyramid), Avi Perez, will deliver a session with Will Blake, Chief Technology Officer of CRU, a global provider of business intelligence and consulting services for the global metals, mining and fertilizer industries, at Big Data LDN (London) on Wednesday 21st September at 12:40 p.m. BST at Olympia London. This historic Victorian exhibition space was founded in 1886 and is steps away from the TfL Kensington (Olympia) station.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220916005057/en/
CRU is a global provider of business intelligence and consulting services for the global metals, mining and fertilizer industries. The headquarters of CRU is located in the heart of London. Will Blake, Chief Technology Officer, will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.
Key Points:
- CRU is a leading London commodities consultancy, relied upon by its clients for expert insight and data on the global metals, mining and fertilizer industries.
- Pyramid Analytics is the provider of the Pyramid Decision Intelligence Platform, the only purpose-built, unified Decision Intelligence Platform.
- Will Blake and Avi Perez will discuss how CRU uses prescriptive analytics and Decision Intelligence from Pyramid within its data analytics pipelines, better equipping customers to tackle key decisions within the commodity markets.
- This panel discussion will take place from 12:40 p.m. – 1:10 p.m. BST in the Modern Analytics Theatre at Big Data LDN.
- Join us at stand 435 to meet the Pyramid team, see demos of the Pyramid Platform, and learn how Decision Intelligence can transform your relationship with data.
- Register for your free tickets and find out more about the session here.
Why Attend
Big Data LDN is a major annual event for the UK data and analytics community, regularly bringing together more than 9,000 leading industry experts and practitioners from around the world for two days packed with seminars and exhibits at the Olympia in the heart of London.
-
Wednesday September 21, 12:40 p.m. – 1:10 p.m. in the Modern Analytics Theatre.
Decision Intelligence and Prescriptive Analytics: How CRU uses Pyramid to Drive its Data Analytic Solutions and Help Businesses Make More Informed Decisions
Presenters: Will Blake, Chief Technology Officer at CRU, and Avi Perez, Chief Technology Officer at Pyramid Analytics
Abstract: This session will be a discussion between two CTOs, both experts on data analytics. It will explore how CRU uses the Pyramid Decision Intelligence Platform within its data analytics pipelines, supporting market analysis and commodity price assessments
Blake and Perez will reveal how CRU restructured its approach to analytics, phasing out siloed approaches that relied on different tools and used the Pyramid Decision Intelligence Platform within its data analytics pipelines
Crucially, Decision Intelligence is founded on the principle of helping anyone secure data-driven insights to make faster, more intelligent decisions. CRU put this principle into action, using prescriptive analytics and Decision Intelligence to tackle major challenges such as reducing carbon emissions and other ESG initiatives. In so doing, CRU continues to transform commodity market data into a valuable business asset.
Decision Intelligence is the Next Big Data Analytics Innovation
“Artificial Intelligence (AI) is an increasingly important analytics technology. But AI to date is limited to highly-trained practitioners, and until now, there has been no easy way to integrate the essential AI components of Data Prep, Business Analytics, and Data Science. The Pyramid Decision Intelligence Platform meets this need: its Decision Intelligence solutions go beyond traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. The Pyramid Platform lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards,” said Blake.
In particular, the Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Decision Intelligence is High-Growth Segment of Augmented Analytics
The growth potential of Decision Intelligence is enormous. Gartner predicts that “more than 33%” of large organizations will be using Decision Intelligence by 2023. Similarly, worldwide spending on big data and business analytics (BDA) solutions was forecast to reach $215.7 billion in 2021, an increase of 10.1% over 2020, according to a recent update from IDC. The compound annual growth rate (CAGR) for global BDA spending over the 2021-2025 forecast period is predicted to be 12.8%.
Pyramid is helping to define this growing market.
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Decision Intelligence Platform provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220916005057/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom